Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Han, C.L.

Refine Results

Resource Type

Availability

Creation Date

Faculty

Collection

Author

Show more

Language

Search results

  • RSS Feed
(1 - 6 of 6)
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
Deodhar, A.; Braun, J.; Inman, R.D.; Heijde, D. van der; Zhou, Y.Y.; Xu, S.; ... ; Hsu, B. 2015
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
Article / Letter to editor
metadata only
The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
Heijde, D. van der; Deodhar, A.; Braun, J.; Mack, M.; Hsu, B.; Gathany, T.A.; ... ; GO-RAISE Investigators 2014
The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
Article / Letter to editor
metadata only
Achieving Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein Major Improvement and Inactive Disease in Patients with Ankylosing Spondylitis after Treatment with Golimumab is Associated with Normalized Health Related Quality of Life: 2-Year R
Inman, R.; Deodhar, A.; Braun, J.; Mack, M.; Hsu, B.; Gathany, T.; ... ; Heijde, D. van der 2013
Achieving Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein Major Improvement and Inactive Disease in Patients with Ankylosing Spondylitis after Treatment with Golimumab is Associated with Normalized Health Related Quality of Life: 2-Year Results from GO-RAISE
Article / Letter to editor
metadata only
ACHIEVING ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE C-REACTIVE PROTEIN MAJOR IMPROVEMENT AND INACTIVE DISEASE IN PATIENTS WITH ANKYLOSING SPONDYLITIS AFTER TREATMENT WITH GOLIMUMAB IS ASSOCIATED WITH NORMALIZED HEALTH-RELATED QUALITY OF LIFE: 2-YEAR R
Heijde, D. van der; Deodhar, A.; Braun, J.; Mack, M.; Hsu, B.; Gathany, T.; ... ; Inman, R.D. 2013
ACHIEVING ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE C-REACTIVE PROTEIN MAJOR IMPROVEMENT AND INACTIVE DISEASE IN PATIENTS WITH ANKYLOSING SPONDYLITIS AFTER TREATMENT WITH GOLIMUMAB IS ASSOCIATED WITH NORMALIZED HEALTH-RELATED QUALITY OF LIFE: 2-YEAR RESULTS FROM GO-RAISE
Article / Letter to editor
metadata only
PREDICTORS OF RADIOGRAPHIC PROGRESSION IN METHOTREXATE-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON ONE-YEAR RADIOGRAPHIC DATA FROM THE GO-BEFORE GOLIMUMAB CLINICAL TRIAL
Emery, P.; Fleischmann, R.; Han, C.L.; Heijde, D. van der; Conaghan, P.; Xu, W.C.; Hsia, E. 2012
PREDICTORS OF RADIOGRAPHIC PROGRESSION IN METHOTREXATE-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON ONE-YEAR RADIOGRAPHIC DATA FROM THE GO-BEFORE GOLIMUMAB CLINICAL TRIAL
Article / Letter to editor
metadata only
Cost Per Placebo Adjusted Response of Golimumab, Adalimumab, and Etanercept in Patients with Active Ankylosing Spondylitis
Braun, A.D.J.; Braun, J.; Inman, R.D.; Heijde, D. van der; Hsu, B.; Tandon, N.; Han, C.L. 2011
Cost Per Placebo Adjusted Response of Golimumab, Adalimumab, and Etanercept in Patients with Active Ankylosing Spondylitis
Article / Letter to editor
metadata only